Sinphar Pharmaceutical Co Ltd (TW:1734) — Stock Price
Sinphar Pharmaceutical Co Ltd (TW:1734) is currently trading at NT$31.90 TWD, up 0.31% today. Over the past 52 weeks, shares have ranged between NT$29.71 and NT$33.80. This page tracks Sinphar Pharmaceutical Co Ltd's live share price on the TW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Sinphar Pharmaceutical Co Ltd (1734) market capitalisation.
Sinphar Pharmaceutical Co Ltd (1734) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Sinphar Pharmaceutical Co Ltd's daily closing share price and trading volume on the TW exchange over the past year, giving a clear view of recent price momentum and liquidity.
Sinphar Pharmaceutical Co Ltd Income Statement — Revenue, Profit & Earnings by Year
Sinphar Pharmaceutical Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$3.37 Billion | NT$3.15 Billion | NT$2.96 Billion | NT$2.86 Billion | NT$2.43 Billion |
| Cost of Revenue | NT$1.91 Billion | NT$1.91 Billion | NT$1.87 Billion | NT$1.77 Billion | NT$1.54 Billion |
| Gross Profit | NT$1.46 Billion | NT$1.24 Billion | NT$1.09 Billion | NT$1.09 Billion | NT$888.71 Million |
| Research & Development | NT$145.37 Million | NT$151.36 Million | NT$132.58 Million | NT$272.16 Million | NT$511.88 Million |
| SG&A | NT$894.66 Million | NT$248.52 Million | NT$224.15 Million | NT$213.06 Million | NT$201.60 Million |
| Total Operating Expenses | NT$1.04 Billion | NT$943.01 Million | NT$803.51 Million | NT$893.50 Million | NT$1.07 Billion |
| Operating Income | NT$416.86 Million | NT$294.01 Million | NT$286.06 Million | NT$197.80 Million | NT$-180.23 Million |
| EBITDA | NT$671.19 Million | NT$601.24 Million | NT$582.94 Million | NT$539.57 Million | NT$109.64 Million |
| EBIT | NT$416.86 Million | NT$343.87 Million | NT$339.42 Million | NT$272.86 Million | NT$-159.73 Million |
| Interest Expense | NT$33.85 Million | NT$36.77 Million | NT$33.71 Million | NT$27.81 Million | NT$24.80 Million |
| Income Before Tax | NT$401.52 Million | NT$307.10 Million | NT$305.71 Million | NT$245.05 Million | NT$-184.53 Million |
| Income Tax Expense | NT$47.25 Million | NT$21.88 Million | NT$-51.07 Million | NT$80.87 Million | NT$20.43 Million |
| Net Income | NT$365.75 Million | NT$304.70 Million | NT$375.17 Million | NT$224.64 Million | NT$-38.13 Million |
Sinphar Pharmaceutical Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Sinphar Pharmaceutical Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$6.15 Billion | NT$6.30 Billion | NT$6.25 Billion | NT$6.19 Billion | NT$6.22 Billion |
| Total Current Assets | NT$2.53 Billion | NT$2.62 Billion | NT$2.65 Billion | NT$2.78 Billion | NT$2.70 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | NT$130.49 Million | NT$102.36 Million | NT$6.66 Million | NT$6.66 Million | NT$50.10 Million |
| Net Receivables | NT$713.86 Million | NT$641.90 Million | NT$643.47 Million | NT$685.19 Million | NT$592.97 Million |
| Inventory | NT$724.69 Million | NT$714.91 Million | NT$876.90 Million | NT$737.01 Million | NT$697.39 Million |
| Property, Plant & Equipment | — | — | — | NT$3.14 Billion | NT$3.22 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | NT$2.44 Billion | NT$2.75 Billion | NT$2.85 Billion | NT$2.97 Billion | NT$3.14 Billion |
| Total Current Liabilities | NT$1.01 Billion | NT$1.42 Billion | NT$1.20 Billion | NT$1.45 Billion | NT$1.53 Billion |
| Long-term Debt | NT$1.27 Billion | NT$1.18 Billion | NT$1.49 Billion | NT$1.42 Billion | NT$1.49 Billion |
| Net Debt | NT$645.77 Million | NT$827.06 Million | NT$870.53 Million | NT$675.96 Million | NT$939.62 Million |
| Total Stockholder Equity | NT$3.44 Billion | NT$3.26 Billion | NT$3.10 Billion | NT$2.93 Billion | NT$2.72 Billion |
| Retained Earnings | NT$364.27 Million | NT$331.30 Million | NT$680.24 Million | NT$444.40 Million | NT$210.68 Million |
Sinphar Pharmaceutical Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Sinphar Pharmaceutical Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$584.66 Million | NT$593.51 Million | NT$296.37 Million | NT$425.30 Million | NT$135.54 Million |
| Capital Expenditures | NT$200.94 Million | NT$256.71 Million | NT$300.94 Million | NT$153.44 Million | NT$161.44 Million |
| Free Cash Flow | NT$383.72 Million | NT$336.80 Million | NT$-4.57 Million | NT$271.85 Million | NT$-25.90 Million |
| Investing Cash Flow | NT$-224.63 Million | NT$-391.08 Million | NT$-334.56 Million | NT$-124.24 Million | NT$-205.60 Million |
| Financing Cash Flow | NT$-576.03 Million | NT$-209.08 Million | NT$-106.84 Million | NT$-263.32 Million | NT$122.95 Million |
| Dividends Paid | NT$181.14 Million | NT$167.72 Million | NT$167.72 Million | NT$33.54 Million | NT$33.54 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | NT$254.33 Million | NT$257.37 Million | NT$243.52 Million | NT$266.71 Million | NT$269.37 Million |
| Change in Cash | NT$-211.53 Million | NT$1.18 Million | NT$-163.07 Million | NT$42.77 Million | NT$51.02 Million |
Sinphar Pharmaceutical Co Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Sinphar Pharmaceutical Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 12, 2025 | 0.59 | 0.41 | +43.90% |
| Mar 20, 2025 | 0.43 | 0.48 | -10.42% |
| Aug 15, 2023 | 0.65 | — | — |
| May 31, 2023 | 0.48 | — | — |
| Mar 29, 2023 | 0.07 | — | — |
| Nov 30, 2022 | 0.41 | — | — |
| Aug 31, 2022 | 0.52 | — | — |
| Jun 01, 2022 | 0.35 | — | — |